[Familial Hypercholesterolemia and Its Related Molecules]

Area of Science:

• Pharmacology and Genetics
• Cardiovascular Disease Research

Background:

• Familial hypercholesterolemia (FH) is a genetic disorder causing premature coronary heart disease due to high LDL cholesterol.
• FH presents an unmet medical need for effective LDL-lowering therapies.

Purpose of the Study:

• To review the scientific development of novel LDL-lowering drugs.
• To discuss challenges in FH diagnosis and treatment.

Main Methods:

• Review of recently approved and investigational LDL-lowering agents.
• Focus on PCSK9 inhibitors (monoclonal antibodies), MTP inhibitors, and antisense oligonucleotides.
• Summary of drug mechanisms and clinical development status.

Main Results:

• Monoclonal antibodies alirocumab and evolocumab (PCSK9 inhibitors) reduce LDL cholesterol by 50-70%.
• Lomitapide (MTP inhibitor) and mipomersen (antisense oligonucleotide) inhibit LDL production.
• Specific approvals in Japan for evolocumab and lomitapide (for homozygous FH) are noted.

Conclusions:

• Novel therapies, particularly PCSK9 inhibitors, show promise for managing elevated LDL cholesterol in FH.
• Further data on long-term efficacy and safety are required for antibody-based PCSK9 inhibitors.
• Underdiagnosis of FH remains a significant clinical problem.